The global size of “Cardiac Marker Testing Market by Biomarker (Troponin, CK-MB, BNP, hs-CRP, Myoglobin), Product (Instrument (Chemiluminescence, ELISA), Reagents & Kits), Disease (MI, CHF, Atherosclerosis), User, ASP & Buying Criteria – Global Forecast to 2028″, is projected to reach USD 6.9 billion by 2028 from USD 4.4 billion in 2023, growing at a CAGR of 9.4% during the forecast period. The expansion of the cardiac marker testing market is propelled by several synergistic factors, including increasing demand for early diagnosis of cardiovascular diseases, escalating cardiovascular diseases prevalence, rising geriatric patient population, growing public-private investments to support for the clinical research of novel cardiac biomarkers and the presence of key market players in developing regions..
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64885447
Key Market Players :
As of 2022, prominent players in the cardiac marker testing market are
- Hoffmann-La Roche AG (Switzerland),
- Abbott Laboratories (US),
- Siemens Healthineers AG (Germany),
- Danaher Corporation (US),
- PerkinElmer, Inc. (US),
- bioMérieux SA (France),
- Bio-Rad Laboratories, Inc. (US),
- Thermo Fisher Scientific Inc. (US),
- DiaSorin (Italy),
- Becton, Dickinson and Company (US),
- Tosoh Corporation (Japan),
- LSI Medience Corporation (Japan),
- Quidel Corporation (US), among others.
Siemens Healthineers AG (Germany): Siemens Healthineers AG is a prominent player in the cardiac marker testing market and has a significant presence in diagnostic segment. The company offers a range of cardiac market testing designed for various cardiovascular diseases treatment. Siemens Healthineers maintains a pioneering position in cardiac marker testing through strategic investments in cutting-edge research and development initiatives. These investments are directed towards enhancing the sensitivity, specificity, and efficiency of cardiac marker assays.
Siemens Healthineers’ unwavering commitment to technological advancement guarantees healthcare providers access to advanced and precise diagnostic solutions, aligning with the highest industry standards. Siemens Healhineers’ comprehensive cardiac marker testing portfolio, combined with its global distribution network and strong brand reputation, positions it as a leading player in the cardiac marker testing market.
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=64885447
Driver: Increase in prevalence of cardiovascular diseases
The escalating prevalence of cardiovascular diseases stands as a significant driving force in the cardiac marker testing industry. This trend underscores a growing demand for advanced diagnostic solutions, compelling the healthcare industry to invest in innovative cardiac marker testing technologies. As heart-related conditions become more prevalent, the market is witnessing a surge in the adoption of these tests, emphasizing the critical need for accurate and efficient diagnostic tools. This demand, fueled by the rising incidence of cardiovascular diseases, is reshaping the landscape of cardiac marker testing and driving advancements in the sector.
Restraint: Issues related to storage and sampling collection
In epidemiological studies, cardiac biomarkers play a crucial role in investigating various stages of diseases in humans. This process necessitates meticulous handling and storage of valuable biological samples to extract extensive information from limited specimens. Maintaining stringent quality control is imperative to ensure the appropriate storage conditions, preventing data loss. The effectiveness of cardiac biomarker studies utilizing archived specimens heavily relies on the integrity of these samples and the methods employed in their processing, collection, and storage. Technical challenges in both sample collection and storage have the potential to impede the growth of the overall cardiac biomarkers market, particularly in the laboratory-based testing segment.
Reagents and kits segment to register significant growth rate over the forecast period of 2022-2028
Based on the product, the cardiac marker testing market is segmented into Reagents and kits and instruments. The surge in cardiovascular diseases and the need for swift heart condition diagnosis have amplified the utilization of reagents and kits in diagnostic laboratories, academic institutions, and point-of-care (POC) facilities. Furthermore, the escalating number of cardiac marker testing procedures and the wider availability of diverse cardiac biomarker kits and reagents are significant contributors to this segment’s substantial market share.
Troponin I and T segment accounted for the significant share of the cardiac marker testing market in 2022-2028
Based on the biomarker type, Troponin is the preferred biomarker for lab professionals in detecting cardiac injuries due to its remarkable sensitivity and specificity. Additionally, the industry’s focus on introducing troponin tests with enhanced sensitivity, enabling the detection of even lower concentrations of troponin in blood samples, is anticipated to bolster the segment’s growth.
Request 10 % Customization: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64885447
North America to account for a significant market share in the cardiac marker testing market in 2022
Based on region, The cardiac marker testing market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with North America dominating the market share in 2021. This dominance in North America is propelled by factors such as a growing elderly population, a high incidence of cardiovascular diseases, an increasing number of cardiac marker testing procedures, and the presence of well-established players with robust cardiac biomarker testing portfolios. Furthermore, government support for the discovery of new cardiac biomarkers is expected to further boost the cardiac marker testing market in North America.
Recent Developments of Cardiac Marker Testing Industry
- In 2023, BD announced that it had received FDA approval for its BD Vacutainer Troponin I Ultra test to be used in point-of-care settings which makes the BD Vacutainer Troponin I Ultra test the first and only FDA-approved point-of-care troponin test for the diagnosis of acute myocardial infarction (AMI).
- In 2023, Bio-Rad launched the Bio-Plex 2300 Troponin I Assay, a new high-sensitivity troponin I test that can detect cardiac damage earlier than other troponin tests.
